FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] AGRAWAL SUDHIR						2. Issuer Name and Ticker or Trading Symbol <u>IDERA PHARMACEUTICALS, INC.</u> [IDRA]									tionship of Reporting Perso all applicable) Director			10% C	10% Owner	
(Last) (First) (Middle) C/O IDERA PHARMACEUTICALS, INC. 167 SIDNEY STREET						3. Date of Earliest Transaction (Month/Day/Year) 11/13/2012								X	Officer (give title below) Chairman, CEO &		EO &	Other (specify below) 2 President		
						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)									X	,										
CAMBRIDGE MA 02139					_										Form filed by More than One Reporting Person					
(City)	(State	e) (Zip)																	
		Tab	e I - N	on-De	rivati	ve S	Securitie	es Acq	uired, I	Disp	osed	of, or Be	ene	ficially	Owned					
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						ear)	2A. Deemed Execution Date, if any (Month/Day/Year)					urities Acquised Of (D) ()			5. Amount Securities Beneficiall Owned Following	ly	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amou	nt (A) (D)	or	Price	Reported Transaction(s) (Instr. 3 and 4)		linsu	. 4)	(
			Table							•		or Benefi le securit			d					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution any (Month/D	n Date, if	4. Trans Code (Ir 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount Securities Underlyin Derivative Security (I and 4)		ring	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		ration	Title	- r	Amount or Number of Shares		Transac (Instr. 4	tion(s)			
Stock Option (Right to Buy)	\$1.157	11/13/2012			A		83,750 ⁽¹⁾		(1)	11/2	8/2021	Common Stock		83,750(1)	\$0.00	365,0	000	D		
Stock Option	\$1.16	11/13/2012			Α		5,863 ⁽²⁾		(2)	11/2	8/2021	Common		5,863(2)	\$ 0	25,5	51	D		

Explanation of Responses:

1. On December 5, 2011, the reporting person was granted an option to purchase up to an aggregate of 500,000 shares of common stock. Half of the shares subject to such option are subject to satisfaction of performance vesting criteria. On November 13, 2012, certain performance vesting criteria were met with respect to 83,750 of such shares, of which 20,937 shares vested on November 13, 2012 and the remaining 62,813 of which will vest in three equal annual installments beginning on November 13, 2013.

2. On January 3, 2012, the reporting person was granted an option to purchase up to an aggregate of 35,000 shares of common stock. Half of the shares subject to such option are subject to satisfaction of performance vesting criteria. On November 13, 2012, certain performance vesting criteria were met with respect to 5,863 of such shares, of which 1,465 shares vested on November 13, 2012 and the remaining 4,398 of which will vest in three equal annual installments beginning on November 13, 2013.

/s/ Sudhir Agrawal 11/15/2012

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

te

OMB APPROVAL